{
    "organizations": [],
    "uuid": "a5d821c57084f53accc4b14d6a465fffb8a61c8a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bayer-receives-approval-for-eylea/brief-bayer-receives-approval-for-eylea-in-china-idUSFWN1SI08X",
    "ord_in_thread": 0,
    "title": "BRIEF-Bayer Receives Approval For Eylea In China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 11 (Reuters) - Bayer AG:\n* SAYS RECEIVES APPROVAL FOR EYLEA IN CHINA * EYLEA GAINS APPROVAL IN CHINA FOR TREATMENT OF VISUAL IMPAIRMENT DUE TO NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION Further company coverage:\n ",
    "published": "2018-05-11T14:05:00.000+03:00",
    "crawled": "2018-05-12T17:32:42.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "bayer",
        "ag",
        "say",
        "receives",
        "approval",
        "eylea",
        "china",
        "eylea",
        "gain",
        "approval",
        "china",
        "treatment",
        "visual",
        "impairment",
        "due",
        "neovascular",
        "wet",
        "macular",
        "degeneration",
        "company",
        "coverage"
    ]
}